Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 30, 2020 Filed Nov 2, 2020 21:41 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,740 | $69.50 | $190,430.00 |
DisclosureSEC source: 0001127602-20-027853 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 332,496 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.00 to $69.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:41 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,500 | $68.24 | $102,360.00 |
DisclosureSEC source: 0001127602-20-027853 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 335,236 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.95 to $68.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 21:41 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,706 | $67.40 | $384,584.40 |
DisclosureSEC source: 0001127602-20-027853 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 336,736 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.92 to $67.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $68.39 | $683,900.00 |
DisclosureSEC source: 0001127602-20-027729 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,694,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-027729 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,603,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $68.75 | $618,750.00 |
DisclosureSEC source: 0001127602-20-027729 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,604,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 300 | $71.13 | $21,339.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 9 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.07 to $71.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,700 | $70.53 | $119,901.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754,897 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.03 to $70.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 3,000 | $69.57 | $208,710.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,756,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.02 to $70.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · derivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,824 Underlying: Common Stock · 5,000 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 2,100 | $70.99 | $149,079.00 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.82 to $71.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 6,844 | $70.21 | $480,517.24 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.81 to $70.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 6,056 | $69.42 | $420,407.52 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.80 to $69.79. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 20:42 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-20-027572 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · derivative · entry 11 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
GiftCommon Stock | 151,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 151,933 F4 · ownership.nature: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
GiftCommon Stock | 151,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759,597 Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 100 | $71.25 | $7,125.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,911,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 7,742 | $70.47 | $545,578.74 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,911,630 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.02 to $71.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 7,158 | $69.52 | $497,624.16 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,919,372 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.00 to $70.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 23, 2020 Filed Oct 28, 2020 00:22 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-027589 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,926,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 20:38 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 600 | $70.98 | $42,588.00 |
DisclosureSEC source: 0001127602-20-027570 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 342,442 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.91 to $71.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 20:38 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,589 | $70.38 | $393,353.82 |
DisclosureSEC source: 0001127602-20-027570 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 343,042 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.90 to $70.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 20:38 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,857 | $69.47 | $337,415.79 |
DisclosureSEC source: 0001127602-20-027570 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 348,631 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.87 to $69.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 20:30 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $68.58 | $685,800.00 |
DisclosureSEC source: 0001127602-20-027457 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,704,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:30 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-027457 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,613,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:30 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $71.31 | $641,790.00 |
DisclosureSEC source: 0001127602-20-027457 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,614,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · derivative · entry 6 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,522 Underlying: Common Stock · 32,000 shares Expires 2028-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F7 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 700 | $71.39 | $49,973.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 5 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.34 to $71.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 15,455 | $70.56 | $1,090,504.80 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 4 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,381 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.27 to $71.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 14,148 | $69.84 | $988,096.32 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 3 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,836 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
SaleCommon Stock | 1,697 | $68.70 | $116,583.90 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 2 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,984 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.20 to $69.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:32 UTC |
HENDERSON LORI M.General Counsel and Secretary
|
Exercise / conversionCommon Stock | 32,000 | $14.85 | $475,200.00 |
DisclosureSEC source: 0001127602-20-027459 · form4.xml · nonDerivative · entry 1 HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020. F2 · balance_after: Includes 681 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| October 20, 2020 Filed Oct 21, 2020 20:04 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 8,455 | $72.05 | $609,182.75 |
DisclosureSEC source: 0001127602-20-027379 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,085,941 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F2 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · derivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · derivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,824 Underlying: Common Stock · 5,000 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 200 | $73.81 | $14,762.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.78 to $73.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 3,100 | $73.12 | $226,672.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.67 to $73.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 6,005 | $71.92 | $431,879.60 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.66 to $72.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 5,695 | $71.24 | $405,711.80 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,305 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.64 to $71.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 21:26 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-20-027281 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 21:24 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,600 | $76.11 | $273,996.00 |
DisclosureSEC source: 0001127602-20-027278 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 353,488 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.75 to $76.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 21:24 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 2,198 | $75.24 | $165,377.52 |
DisclosureSEC source: 0001127602-20-027278 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 357,088 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 21:24 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,248 | $74.17 | $389,244.16 |
DisclosureSEC source: 0001127602-20-027278 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 359,286 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.70 to $74.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $75.48 | $754,800.00 |
DisclosureSEC source: 0001127602-20-027086 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,714,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 20:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-027086 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 20:45 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $79.81 | $718,290.00 |
DisclosureSEC source: 0001127602-20-027086 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,624,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.